Contract Manufacturing, Biopharmaceutical Production

Avid Bioservices Expands Biologics Manufacturing Capacity

February 22, 2021

The second phase of the Myford facility expansion in California will add upstream and downstream processing suites.

Novavax Expands COVID-19 Collaboration and License Agreement with SK Bioscience

February 17, 2021

The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.

Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab

February 04, 2021

The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.

Evonik Supplies Key LNP Technology for Gene-Based Drugs

December 10, 2020

Evonik offers lipid nanoparticles for gene-based drug development and manufacturing.

Samsung Biologics Begins Construction on Fourth Biopharma Manufacturing Plant

November 23, 2020

The new super plant, being built in Incheon, South Korea, will have a total biopharmaceutical manufacturing capacity of 256,000 L.

Samsung Biologics and Lilly Partner to Accelerate Delivery of COVID-19 Antibody Therapeutics

November 23, 2020

The companies have formed a long-term manufacturing agreement to accelerate the global supply for Lilly’s COVID-19 antibody therapeutics.

Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination

November 03, 2020

The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.

MilliporeSigma Invests $65 Million to Expand Antibody-Drug Conjugate Manufacturing

September 09, 2020

The investment at its Madison, WI, facility will expand MilliporeSigma’s capacity for high-potent active pharmaceutical ingredient production and allow for continuous flow manufacturing of ADCs.

Catalent Invests $130 Million to Expand Gene Therapy Manufacturing Capacity

September 09, 2020

The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.

Preparing Pandemic Vaccine Capacity

September 02, 2020

Rapid scale-up to billions of doses requires collaborative, all-out efforts by innovators, their manufacturing partners, and the entire supply chain.